Legend Biotech Corporation American Depositary Shares (LEGN)
Legend Biotech to set up new R&D facility in Philadelphia
Legend Biotech said on Thursday it would set up a new research and development facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Friday, Legend Biotech Corporation LEGN and Johnson & Johnson JNJ announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study.
Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Carvykti, a CAR-T therapy co-developed by Legend Biotech & J&J, is central to second-line multiple myeloma treatment. Both firms are actively scaling up production across bases. Carvykti sales surged 60% YoY, reaching US$343 million in 1H2024, forecasting US$1 bilion+ for the full year. Rumors since July claim Legend Biotech faced a takeover bid, with fresh whispers of pricing disputes in negotiations this week.
Legend Biotech Corporation (LEGN) Q2 2024 Earnings Call Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2024 Earnings Call Transcript August 9, 2024 8:00 AM ET Company Participants Jessie Yeung - VP of IR & Finance Ying Huang - CEO Lori Macomber - CFO Steve Gavel - Head of Commercial Development for US and Europe Guowei Fang - CSO Conference Call Participants Gena Wang - Barclays Jessica Fye - JPMorgan Kelly Shi - Jefferies Ash Verma - UBS Leonid Timashev - RBC Capital Markets Jonathan Miller - Evercore ISI Yaron Werber - TD Cowen James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Justin Zelin - BTIG Mitchell Kapoor - H.C. Wainwright George Farmer - Scotiabank Rick Bienkowski - Cantor Fitzgerald Sean McCutcheon - Raymond James Asthika Goonewardene - Truist Operator Ladies and gentlemen, thank you for standing by.
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Shares of cell therapy company Legend Biotech Corp LEGN were trading lower on Monday, after being among the top pharma gainers in the first week of June.
